Arcutis Biotherapeutics, Inc. (ARQT) vs Tarsus Pharmaceuticals, Inc. (TARS)
- Arcutis Biotherapeutics, Inc. ARQT 28.82 −0.96%
- Tarsus Pharmaceuticals, Inc. TARS 68.07 −4.11%
Arcutis Biotherapeutics, Inc. and Tarsus Pharmaceuticals, Inc. are both Biotechnology companies. Arcutis Biotherapeutics, Inc. and Tarsus Pharmaceuticals, Inc. are of similar size ($3.7B and $3.5B). Tarsus Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Arcutis Biotherapeutics, Inc. trades at 131×. Tarsus Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 105.2% against 76.1%. Arcutis Biotherapeutics, Inc. has the higher net margin (6.15% vs −7.67%) and the higher return on invested capital (23.6% vs 0.00%). Across the 18 metrics below, Tarsus Pharmaceuticals, Inc. leads on 11 and Arcutis Biotherapeutics, Inc. on 7.
Valuation
Profitability
| Metric | ARQT | TARS | Biotechnology median |
|---|---|---|---|
| Gross margin | 91.14% | 93.28% | 65.16% |
| Operating margin | 7.38% | (8.00%) | 0.00% |
| Net margin | 6.15% | (7.67%) | 0.00% |
| Free cash flow margin | 8.42% | 9.24% | 0.00% |
| Return on equity | 15.86% | (13.68%) | (56.36%) |
| Return on assets | 6.78% | (8.40%) | (48.04%) |
| Return on invested capital | 23.62% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack